Abiraterone acetate - Churchill Pharmaceuticals

Drug Profile

Abiraterone acetate - Churchill Pharmaceuticals

Alternative Names: submicron abiraterone acetate

Latest Information Update: 03 Jun 2016

Price : $50

At a glance

  • Originator Churchill Pharmaceuticals
  • Class Androstenols; Antiandrogens; Antineoplastics; Small molecules
  • Mechanism of Action CYP17A1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Prostate cancer

Most Recent Events

  • 03 Jun 2016 Churchill Pharmaceuticals in-licenses the SoluMatrix™ Fine Particle technology from iCeutica (iCeutica website, June 2016)
  • 03 Jun 2016 Phase-II clinical trials in Prostate cancer (Metastatic disease, Second-line therapy or greater) in USA (unspecified route) (NCT02737332)
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top